Myrexis, Inc.
Myrexis, Inc. is a New York-based life sciences company that suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012 and is currently evaluating strategic alternatives focused on financial investments in life sciences assets.
- Company typePrivate
- Founded1999
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Myrexis, Inc. does
Myrexis, Inc. is a New York-based life sciences company that suspended all of its preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. Following this suspension, the company ceased active research and product development activities and shifted to evaluating strategic alternatives, with a stated focus on identifying and making financial investments in life sciences assets. The company is no longer developing or commercializing pharmaceutical products and has no disclosed customers, revenue streams, or active partnerships.
The company is managed by a single executive, Jonathan Couchman, who holds the roles of President, CEO, CFO, and Director — a consolidation that reflects the company's minimal operational footprint. Mr. Couchman concurrently serves in the same capacities at Xstelos Holdings, Inc., and the company's registered office is co-located with Couchman Management LLC at 600 Fifth Avenue in New York. Reported financial figures appear anomalous, showing multi-trillion-dollar EBITDA and net loss figures that suggest either data corruption, distressed reporting, or unit-misstated figures rather than meaningful operational performance.
Myrexis currently operates as a shell company in strategic alternatives evaluation mode. There are no active product candidates, no clinical pipeline, no disclosed intellectual property under active development, and no commercial operations. The company's sole forward-looking activity is the evaluation of potential financial investments in external life sciences assets, positioning it as a potential investment vehicle rather than an operating business.
Myrexis, Inc. firmographics
Firmographics- Name
- Myrexis, Inc.
- Legal name
- Myrexis, Inc.
- Website
- https://myrexis.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Myrexis, Inc. is a New York-based life sciences company that suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012 and is currently evaluating strategic alternatives focused on financial investments in life sciences assets.
- Ownership category
- akta.pro rank
Myrexis, Inc. industry classification
Industry- Product category
- Pharmaceutical Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Myrexis, Inc. is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Myrexis, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Others
Revenue model
- Financial Investments in Life Sciences: The company is currently focused on identifying, evaluating, and making financial investments in life sciences assets as part of its strategic alternatives evaluation. No active product revenue is being generated from suspended development programs.
Go-to-market motion1 record
Myrexis, Inc. product offering
Product offeringCore offering
Myrexis, Inc. is a New York-based life sciences company that historically conducted preclinical and clinical development of small molecule therapeutics for oncology and autoimmune diseases. In February 2012, the company suspended all such development programs and is now focused on evaluating strategic alternatives, including identifying, evaluating, and making financial investments in life sciences assets.
Product overview
Myrexis, Inc. is a life sciences company headquartered in New York that is currently in the process of evaluating strategic alternatives, including identifying and making financial investments in life sciences assets. The company suspended all preclinical and clinical development programs in oncology and autoimmune diseases in February 2012. No active products or services are currently being offered based on the available information.
Differentiator
Problem solved
Functional benefit
Myrexis, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Myrexis, Inc. partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights1 record
Myrexis, Inc. competitors and assessment
Company assessmentBroad incumbents
- Regeneron Pharmaceuticals, Inc. Regeneron is a leading biotechnology company with strong franchises in ophthalmology, immunology, and oncology. It is a broad incumbent that competes in the inflammation and oncology therapeutic spaces where Myrexis once operated.
- AbbVie Inc. AbbVie is a global biopharmaceutical company with a flagship immunology franchise (Humira/Skyrizi/Rinvoq). It is the dominant incumbent in the autoimmune/immunology therapeutic area that was one of Myrexis's two historical focus areas.
- Pfizer Inc. Pfizer is a leading global pharmaceutical company with major oncology and immunology pipelines. It is a broad incumbent in the same therapeutic categories Myrexis once targeted and would be a logical acquirer of any revived Myrexis assets.
- Amgen Inc. Amgen is a major biotechnology company with established franchises in oncology and inflammation/autoimmune diseases, mirroring Myrexis's two historical therapeutic areas. It serves as a broad benchmark for the therapeutic categories Myrexis once operated in.
- Bristol-Myers Squibb Company: Bristol-Myers Squibb is a major branded pharmaceutical company with significant franchises in oncology and immunology/inflammation — the exact therapeutic categories that Myrexis historically pursued before suspending its programs. It represents the type of large incumbent that would have been a competitor or acquirer in Myrexis's active phase.
Direct peers
- Xstelos Holdings, Inc. Xstelos Holdings is a publicly traded shell/holding company whose President, CEO, CFO and Chairman is Jonathan Couchman — the same individual who leads Myrexis. The two entities share a CEO/CFO and a similar shell structure, making Xstelos the closest structural peer to Myrexis.
- Pernix Therapeutics Holdings, Inc. Pernix Therapeutics was a small specialty pharmaceutical company where Jonathan Couchman previously served on the board. Like Myrexis, it operated in the specialty pharma space with a narrow product portfolio and was subject to strategic restructurings, making it a relevant historical comparison point.
Emerging players
- Vertex Pharmaceuticals Incorporated: Vertex is a specialty biopharmaceutical company focused on small-molecule therapeutics in niche indications — analogous to Myrexis's original model of pursuing smaller-scale drug development in specific disease areas before suspending its programs.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights3 records
Customer concentration
Myrexis, Inc. social profiles
Digital presenceMyrexis, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Myrexis, Inc. leadership team
Management profileNumber of profiles
Profiles1 record
Myrexis, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Myrexis, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Myrexis, Inc.
What does Myrexis, Inc. do?
Myrexis, Inc. is a New York-based life sciences company that historically conducted preclinical and clinical development of small molecule therapeutics for oncology and autoimmune diseases. In February 2012, the company suspended all such development programs and is now focused on evaluating strategic alternatives, including identifying, evaluating, and making financial investments in life sciences assets.
When was Myrexis, Inc. founded?
Myrexis, Inc. was founded in 1999. It employs 11 to 50 people.
Where is Myrexis, Inc. based?
Myrexis, Inc. is headquartered in New York, United States, in the North America region.
How does Myrexis, Inc. make money?
One revenue line is on record: financial Investments in Life Sciences.
Who are Myrexis, Inc.'s main competitors?
Broad incumbents on record are Regeneron Pharmaceuticals, Inc., AbbVie Inc., Pfizer Inc., Amgen Inc. and Bristol-Myers Squibb Company. Direct peers are Xstelos Holdings, Inc. and Pernix Therapeutics Holdings, Inc.. Vertex Pharmaceuticals Incorporated is listed as an emerging player.
Does Myrexis, Inc. have an API?
No public API is recorded for Myrexis, Inc..
What industry is Myrexis, Inc. in?
Myrexis, Inc.'s product category is Pharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.